Succeeding in Breaking the R-CHOP Ceiling in DLBCL: Learning From Negative Trials
- PMID: 28926287
- DOI: 10.1200/JCO.2017.74.7360
Succeeding in Breaking the R-CHOP Ceiling in DLBCL: Learning From Negative Trials
Comment in
-
Through the Glass Ceiling.J Clin Oncol. 2018 Mar 20;36(9):923. doi: 10.1200/JCO.2017.76.3961. Epub 2018 Jan 25. J Clin Oncol. 2018. PMID: 29369698 No abstract available.
-
Reply to H. Tilly et al.J Clin Oncol. 2018 Mar 20;36(9):923-925. doi: 10.1200/JCO.2017.76.8754. Epub 2018 Jan 25. J Clin Oncol. 2018. PMID: 29369704 No abstract available.
Comment on
-
Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.J Clin Oncol. 2017 Nov 1;35(31):3529-3537. doi: 10.1200/JCO.2017.73.3402. Epub 2017 Aug 10. J Clin Oncol. 2017. PMID: 28796588 Clinical Trial.
-
Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.J Clin Oncol. 2017 Nov 1;35(31):3538-3546. doi: 10.1200/JCO.2017.73.2784. Epub 2017 Sep 1. J Clin Oncol. 2017. PMID: 28862883 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
